Skip to content
CompletedPhase 1 / Phase 2

Clinical Study of GH001 in Depression

NCT04698603 · GH Research Ireland Limited

Closed to entry
Status
Not accepting participants
Phase 1 / Phase 2
Phase
16
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

The aim of the study is to investigate the safety of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT), and to investigate its effects on severity of depressive symptoms, and its dose-related psychoactive effects in patients with Treatment-Resistant Depression (TRD). The study is comprised of two open-label, single-arm study parts where Part A evaluates single doses of GH001 at two dose levels and Part B evaluates a specific individualized dosing regimen of GH001.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Phase 1: The safety and tolerability of GH001 as a combined measure of outcomes 5 to 13.

    Measured over up to 7 days

  • Phase 2: The effects of GH001 on the severity of depression evaluated by the Montgomery-Asberg Depression Rating Scale (MADRS)

    Measured over up to 7 days

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 64 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Has a body mass index (BMI) in the range of 18.5 and 35.0 kg/m2 (inclusive); * Meets the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria for single-episode major depressive disorder (MDD) or recurrent MDD, without psychotic features confirmed by the Mini-International Neuropsychiatric Interview (MINI); * Treatment-Resistant Depression as evaluated by the Antidepressant Treatment History Form - Short Form (ATHF-SF); * Has outpatient status at screening and enrolment visits; Exclusion Criteria: * Has a current or prior diagnosis of a psychiatric comorbidity that renders the patient unsuitable for the study according to a study psychiatrist or registered psychologist; * Has received any investigational medication within the last 1 month; * Has a current medically significant condition (e.g., severe infection) or has a history of a medically significant condition (e.g., medical history of seizure, uncontrolled hypertension, uncontrolled diabetes, severe cardiovascular disease, hepatic or renal failure, etc.) that renders the patient unsuitable for the study according to the medical supervisor's judgment; * Takes any medication or other substance that renders the patient unsuitable for the study according to the medical supervisor's judgment; * Has a clinically significant abnormality in physical examination, vital signs, ECG, or clinical laboratory parameters, which renders the patient unsuitable for the study according to the medical supervisor's judgment;

Where

1 study site

FacilityCityRegionCountry
Clinical Trial SiteMaastrichtNetherlands

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT04698603 on ClinicalTrials.gov →

Last updated in the registry 2023-08-15. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits